Vaccinex reports 2 complete responses in first 3 patients in Phase 1b KEYNOTE-B84 study for HNSCC

VACCINEX, INC.

Two of three patients in Phase 1b safety segment achieved complete responses per RECIST v1.1.
Both responders had low PD-L1 expression (CPS<20); HPV-negative status.
Third patient had clinical progression and withdrew before week 9; SAEs attributed to pre-existing condition.
Expansion phase now open; will enroll up to 62 additional patients across 18 US sites.
Data safety monitoring board confirmed pepinemab (20 mg/kg Q3W) + KEYTRUDA (200 mg Q3W) well-tolerated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.